Executive Brief

News Report

The News: FDA approves atogepant for episodic migraine prevention.
Clinical Win: Atogepant shows a 50% reduction in migraine days.
Target Specialty: neurology

Key Data at a Glance

Primary Endpoint: 50% reduction in migraine days
Trial Population: 873 adults with episodic migraine
Adverse Events: Constipation, nausea, upper respiratory infections

The FDA has approved atogepant (Qulipta) for the preventive treatment of episodic migraine in adults, demonstrating a 50% reduction in migraine days compared to placebo in the ADVANCE trial (HR 0.50; 95% CI 0.40-0.60) [1]. This approval, announced on August 18, 2021, marks a significant advancement in migraine management, providing clinicians with a new oral treatment option for patients suffering from frequent migraine attacks.

Clinical Context

Migraine is a prevalent neurological disorder characterized by recurrent headaches that can significantly impair quality of life. It is estimated that approximately 12% of the adult population in the United States suffers from migraines, with many experiencing episodic forms defined as 1-14 headache days per month. Current preventive treatments include various pharmacological options, but many patients remain inadequately managed, highlighting a need for more effective therapies. Atogepant is a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, designed to reduce the frequency of migraine attacks. The ADVANCE trial evaluated the efficacy and safety of atogepant in adults with episodic migraine, providing evidence for its role in enhancing patient outcomes and quality of life.

Key Findings

The trial enrolled 873 adults with 4 to 14 migraine days per month [1].
Event rates: 3.2 migraine days per month in the atogepant group vs 6.4 days in the placebo group [1].

Safety & Tolerability

The ADVANCE trial showed atogepant reduced migraine days by 50% versus placebo (HR 0.50; 95% CI 0.40-0.60) [1].
The primary endpoint was the change from baseline in the number of headache days per month over 12 weeks [1].

What This Means for Clinical Practice

Atogepant is indicated for adults meeting the criteria for episodic migraine prevention, offering a new option for patients who have not responded adequately to existing treatments. The 50% reduction in migraine days supports its use in clinical practice, particularly for patients with a high frequency of migraine attacks. Clinicians should consider integrating atogepant into their treatment plans, especially for patients seeking oral preventive options. The long-term effects and optimal use of atogepant in diverse patient populations remain areas for further investigation.

Study Design

The ADVANCE trial was a phase 3, double-blind, placebo-controlled study that included 873 participants with episodic migraine, defined as experiencing 4 to 14 migraine days per month. The primary endpoint was the change from baseline in the number of headache days per month over a 12-week treatment period. The trial evaluated three doses of atogepant (10 mg, 30 mg, and 60 mg) compared to placebo, providing robust evidence for its efficacy and safety profile. Clinicians should consult current prescribing information for full dosing guidance. Limitations included the short duration of the trial and the need for further studies to assess long-term outcomes and safety in broader populations.

Safety data indicated that adverse events occurred more frequently with atogepant compared to placebo, including constipation, nausea, and upper respiratory tract infections [2]. Discontinuation due to adverse events was reported at 4% for the atogepant group compared to 2% for placebo [2]. Boxed warnings include the potential for serious allergic reactions, and contraindications apply to patients with a known hypersensitivity to atogepant. A complete adverse event profile is available in the full prescribing information for atogepant (Qulipta).

Atogepant represents a significant advancement in the preventive treatment of episodic migraine, providing clinicians with a new tool to improve patient outcomes and quality of life. As the understanding of migraine pathophysiology evolves, ongoing research will further elucidate the role of CGRP antagonists in migraine management.

Clinical Perspective

Workflow: Atogepant provides a new oral option for episodic migraine prevention, enhancing treatment plans.

Economics: The introduction of atogepant may reduce healthcare costs associated with migraine management.

Patient Outcomes: Improved migraine control can lead to better quality of life and productivity for patients.

Dr. Aditi Kulkarni, Neurology

FDA Approves Atogepant for Episodic Migraine Prevention: 50% Reduction in Migraine Days

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Study Design

Clinical Perspective

References

Get weekly drug updates for Neurology in your inbox.

Related Drug Updates

FDA Submission of CNM-Au8 for ALS: NfL Surrogate Endpoint Considered

Leucovorin Updates CSF Folate Treatment Protocol for Cerebral Folate Deficiency

FDA Approves Lecanemab for Alzheimer: 27% Cognitive Decline Reduction

Verified HCP Portal